Efficacy and safetyof levitra (vardenafil) in the treatment of erectile dysfunction4


Cite item

Full Text

Abstract

References

  1. Junemann К. P., Persson-Junemann С., Aiken P. Pathophysiology of erectile dysfunction. Semin. Urol. 1990; 144: 80.
  2. Hatzichristou D. G., Pescatori E. S. Current treatments and emerging therapeutic approaches in male erectile dysfunction.Br. J. Urol. 2001; 88 (suppl. 3): 11-17.
  3. Schramek P., Dorninger R., Waldhauser M. et al. Prostaglandin El in erectile dysfunction. Efficiency and incidence of priapism.Br. J. Urol. 1990; 65: 68-71.
  4. Porst H. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil - a comparative study in 103 patients with erectile dysfunction. Int. J. Impot. Res. 1997; 9: 187-192.
  5. Brock G. Oral agents: First-line therapy for erectile dysfunction. Eur. Urol. 2002; suppl. 1: 12-18.
  6. Wallis R. M., Corbin J. D., Francis S. H., Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am.J. Cardiol. 1999; 83 (suppl. 5A): 3C-12C.
  7. Fisher W., Eardley J., Rosen R. et al. The Men's Attitudes to Life Events Sexuality (MALES) Study Phase-2: Correlates of self-reported disease severity among men with erectile disfunction. Progr. Urol. 2003; 13 (suppl. 2): 32, abstr. 102.
  8. Feldman H. A., Goldstein L., Hatzichristou D. G. et al. Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging Study. J. Urol. (Baltimore) 1994; 151: 54-61.
  9. Morgentaler A. Male impotence. Lancet 1999; 354: 1713-1718.
  10. McVary К. Т., Carrier S., Wessells H. et al. Smoking and erectile dysfunction: evidence-based analysis. J. Urol. (Baltimore) 2001; 166: 1624-1632.
  11. Niederberger C., Lonsdale J. Erectile dysfunction - patient characteristics and attitudes based on a large-scale male health study conducted in US, Europe, Mexico and Brazil. J. Urol. (Baltimore) 2002; 167 (4): 148.
  12. Porst H., Rosen R. et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at home trial. Int.J. Impot. Res. 2001; 13: 192-199.
  13. Bischoff E., Niewohner U., Haning H. et al. The inhibitory selectivity of vardenafil on bovine and human recombinant phosphodiesterase isoenzymes. Int. J. Impot. Res. 2001; 13 (suppl. 4): 41.
  14. Gbekor E., Bethell S., Fawcett L. et al. Phosphodiesterase 5 inhibitor profiles against all human phosphodiesterase families: Implications for use as pharmacological tools. J. Urol. (Baltimore) 2002; 167 (suppl. 246): abstr. 967.
  15. Sorbera L. A., Martin L., Rabasseda X., Castaner J. Vardenafil. Drugs of the Future 2001; 26: 141-144.
  16. Bauer R.-J., Rohde G., Wensing G. The interaction of alcohol with vardenafil, a potent and highly selective phosphodiesterase type 5 inhibitor T. Pharmacotherapy 2002; 22: 418.
  17. Sachse R., Rohde G., Stark S., Klotz T. Safety, tolerability and pharmacokinetics of BAY 38-9456 in patients with erectile dysfunction. J. Urol. (Baltimore) 2000; (suppl.): abstr. 2693.
  18. Klotz Т., Sachse R., Heidrich A. et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. Wld J. Urol. 2001; 19: 32-39.
  19. Stark S., Sachse R., Liedl T. et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur. Urol. 2001; 40: 181-190.
  20. Mazzu A., Taylor Т., Bauer R.-J. et al. A single oral dose of vardenafil had no acute effect on sperm motility in healthy males.J. Androl. 2002; 23 (suppl. 1): 2.
  21. Hellstrom W. Vardenafil: a new approach to the treatment of erectile dysfunction. Curr. Urol. Rep. 2003; 4: 479-487.
  22. Potempa A.-J., Bernard L., Ulbrich E. Vardenafil improved erectile function in a 'real world' flexible dose regimen. Eur. Urol. 2003; suppl. 2: 96.
  23. Hatzichristou D., Montorsi F., Teylor T. Efficacy of vardenafil in a flexible dose regimen: a placebo-controlled trial. J. Androl. 2003; March/April, suppl.: 48.
  24. Cappelleri J. C., Rosen R. C., Smith M. D. et al. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346-351.
  25. Hellstrom W. J. G., Gittelman M., Karlin G. et al. Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomised, double-blind, placebo-controlled trial. J. Androl. 2002; 23: 763-771.
  26. El-Galley R., Rutland H., Talk R. et al. Long-term efficacy of sildenafil and tachyphylaxis effect. J. Urol. (Baltimore) 2001; 166: 927-931.
  27. Saenz de Tejada I., Glina S., Becher E. et al. Exhibits long-term efficacy and safety of Vardenafil: a 12 month double-blind study.Int. J. Impot. Res. 2002; 14 (suppl. 3): 35.
  28. Donatucci C., Karlin G., Goldfischer E. et al. Influence of age on the efficacy and safety of vardenafil, a novel phosphodiesterase inhibitor for the treatment of erectile dysfunction. J. Am. Geriatr. Soc. 2002; 50: 107.
  29. Donatucci C., Eardley L, McVary К. Т., Thibonnier M. Vardenafil improves erectile function regardless of etiology or baseline severity in men with erectile dysfunction. J. Urol. (Baltimore) 2002; 167 (4, suppl.): 178.
  30. Goldstein I., Young J. M., Fischer J. et al. Vardenafil, a new highly selective PDE5 inhibitor, improves erectile function in patients with diabetes mellitus. Diabetes 2001; 50 (suppl. 2): 114.
  31. Brock G., Taylor Т., Seger M. and the Vardenafil PROSPECT Group. Efficacy and tolerability of vardenafil in men with erectile dysfunction following radical prostatectomy. Eur. Urol. 2002; suppl. 1: 152.
  32. Carson G., Hatzichristou D. et al. Vardenafil exhibits efficacy in men with erectile dysfunction unresponsive to prior sildenafil therapy: results of a phase-Ill clinical trial-patient response with vardenafil in sildenafil nonresponders (PROVEN). Int. J. impot. Res. 2003; 15 (5): S175.
  33. Thadani U., Smith W. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J. Am. Coll. Cardiol. 2002; 40 (11): 2006-2012.
  34. Carson С. С., Burnet A. L., Levine L. A. et al. The efficacy of sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 2002; 60: 12-27.
  35. Brock G. В., McMahon С. G., Chen К. К. et al. Efficacy and safety of Tadalafil for treatment of erectile dysfunction: results of integrated analyses. J. Urol. (Baltimore) 2002; 168: '1332- 1336.
  36. Ormrod D., EasthopeS. E., Figgitt D. P. Vardenafil. Drugs Aging 2002; 19: 217-227.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies